June 23, 2017 8:13 PM ET

Pharmaceuticals

Company Overview of Rapamycin Holdings, Inc.

Company Overview

Rapamycin Holdings, Inc., a drug development company, provides rapamycin-related discoveries applicable to the veterinary and human markets. It offers discoveries for implications in improving an individual's health-span and in fighting age-related medical conditions. The company was incorporated in 2012 and is headquartered in San Antonio, Texas.

12500 Network Boulevard

Suite 105

San Antonio, TX 78249

United States

Founded in 2012

Phone:

210-478-8678

Key Executives for Rapamycin Holdings, Inc.

Chief Executive Officer, President and Director
Chief Financial Officer, Secretary and Treasurer
Director of Medical Affairs
Chief Scientific Officer
Compensation as of Fiscal Year 2016.

Rapamycin Holdings, Inc. Key Developments

Rapamycin Holdings Seeks Major Funding Infusion

Rapamycin Holdings, Inc. is looking to raise as much as $10 million in additional investor support to boost its commercialization efforts.

Rapamycin Holdings, Inc. Opens Investigational New Animal Drug Application with the FDA Center for Veterinary Medicine

Rapamycin Holdings, Inc. has opened an Investigational New Animal Drug (INAD) application for the therapeutic use of the company’s eRapa-NP2gTM compound in the treatment of Feline Chronic Gingivostomatitis (FCGS). FCGS is a debilitating condition that affects the oral cavity in approximately 200,000 domestic cats annually. Symptoms of this disease include reluctance to eat, pain when opening the mouth or swallowing, increased salivation, and vocalization after taking a bite to eat. Medical management and treatment of this condition is often frustrating, with complete full mouth extractions being the only option these cats have for resolution of symptoms. Early pre-clinical studies completed by RHI show that the use of eRapa-NP2gTM to address FCGS resulted in: 44% Complete Remission; 94% >50% Improvement; 78% Average improvement; In addition, these studies show that the company’s eRapaTM compound induced decreases in gum tissue immune, inflammatory and abnormal vascular conditions.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Rapamycin Holdings, Inc., please visit rapamycinholdings.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.